Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals Revenues: 231.79M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
REGN Revenues Rankings
| Overall | 62nd percentile | 1655 of 4432 |
| Sector | 77th percentile | 108 of 471 in Healthcare |
| Industry | 92nd percentile | 10 of 132 in Biotechnology |
REGN Revenues Range, Past 5 Years
| Minimum | 22.20M | Jun 2007 |
| Maximum | 231.79M | Mar 2012 |
| Average | 93.18M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these REGN related companies
REGN News
$REGN finally crakkin a lil, stood stiff longer then most today
about 9 hours ago by HighGrowthFinancial
about 9 hours ago by HighGrowthFinancial
$REGN a few years ago was worth looking at...i implore you to watch $THLD!!!
about 22 hours ago by SirPerfluous
about 22 hours ago by SirPerfluous
Sanofi (SNY), Regeneron (REGN) Report Additional Positive Data from Study 1003 in Patients w/ heFH
May 29, 6:52AM Street Insider
May 29, 6:52AM Street Insider
Throwing my selective disclosure op-ed out there 1 final time. Have a great weekend. See you Tues. http://stks.co/3zje $FB $JPM $REGN $DNDN
about 6 days ago by bradloncar
about 6 days ago by bradloncar
$REGN Insider Sale: $2.5M of stock sold by Eric Shooter between May 18, 2012 - May 21, 2012 http://stks.co/3vHK
about 10 days ago by MarketBrief
about 10 days ago by MarketBrief
@HighGrowthFinancial et tu $REGN ? Now we're really talking the last dominoes to fall, as we all move into walmart ;o)
about 13 days ago by ronin245
about 13 days ago by ronin245
Finding buyers near its rising 20dma. A biotech that has already doubled ytd $REGN http://chart.ly/f5kwout
about 21 days ago by ivanhoff
about 21 days ago by ivanhoff
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
May 10, 9:30AM PR Newswire
May 10, 9:30AM PR Newswire
watching the channel shrink on $REGN .Tomarrow I think we test $125.00
about 22 days ago by HighGrowthFinancial
about 22 days ago by HighGrowthFinancial
Jefferies Trims Target on Regeneron Pharma (REGN) After Arcalyst News, Keeps Buy Rating
May 09, 11:59AM Street Insider
May 09, 11:59AM Street Insider
$PRAA broke resistance. now long $PRAA. Short $SODA. short $REGN.
about 22 days ago by Bobbin4apples
about 22 days ago by Bobbin4apples
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
May 09, 9:30AM PR Newswire
May 09, 9:30AM PR Newswire
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
May 08, 5:04PM PR Newswire
May 08, 5:04PM PR Newswire
FDA panel won't back Regeneron's $REGN Arcalyst for the treatment of gout; vote was unanimous at 11-0
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
FDA panel won't back Regeneron's (REGN) Arcalyst for the treatment of gout
May 08, 3:26PM Street Insider
May 08, 3:26PM Street Insider
Regeneron (REGN) Shares Swing as FDA Panel Votes Against Safety of Arcalyst
May 08, 3:23PM Street Insider
May 08, 3:23PM Street Insider
FDA panel votes 8-3 Regeneron's $REGN Arcalyst unsafe in gout flares
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
FDA panel votes 6-5 Regeneron's $REGN Arcalyst works for Gout flares
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
Regeneron (REGN), Bayer Report Co-Promotion Agreement for EYLEA in Japan
May 08, 8:35AM Street Insider
May 08, 8:35AM Street Insider
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
May 08, 2:00AM PR Newswire
May 08, 2:00AM PR Newswire
@mitrado I had options on $REGN & sold w nice profit & then watched it go up 40pts. more ..really painful
about 24 days ago by teddowns
about 24 days ago by teddowns
@ThanhVII PT for $VRTX was around 44$ Now? Who knows? Sold at 54$ --- Not being greedy here, even though I feel it can be the next $REGN :-P
about 24 days ago by mitrado
about 24 days ago by mitrado
Very strong stock. Had a very nice run and now in bull flag. $REGN http://chart.ly/nupx2qp
about 26 days ago by CubanMark
about 26 days ago by CubanMark
$REGN Insider Sale: $4.3M of stock sold by Murray Goldberg between May 2, 2012 - May 3, 2012 http://stks.co/3fuY
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
Baird Maintains an 'Outperform' on Regeneron Pharma (REGN); Still Taking Share AND Growing the Branded Market
Apr 25, 11:05AM Street Insider
Apr 25, 11:05AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| REGN | 135.89 | +0.14 | +0.10% | 12.75B |
| REG | 43.82 | +0.48 | +1.11% | 3.897B |
| REFR | 3.30 | -0.02 | -0.60% | 62.78M |
| RE | 102.14 | +0.92 | +0.91% | 5.440B |
| RDY | 29.43 | -0.39 | -1.31% | 5.054B |
| RDWR | 38.36 | +0.12 | +0.31% | 803.42M |
| RDSA | 62.19 | +0.39 | +0.63% | 192.20B |
| RDS.B | 64.32 | +0.48 | +0.75% | 199.81B |
| RDNT | 2.40 | +0.03 | +1.27% | 88.71M |
| RDN | 2.48 | +0.00 | +0.00% | 330.56M |